Finding new hits in neglected disease projects: Target or phenotypic based screening?

Current Topics in Medicinal Chemistry

Volumn 11, Issue 10, 2011, Pages 1284-1291

  Gilbert, Ian H ^a   Leroy, Didier ^b   Frearson, Julie A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Medicines for Malaria Venture   (Switzerland)

Author keywords

Chagas disease; Drug discovery; Human African trypanosomiasis; Leishmaniasis; Malaria; Screening

Indexed keywords

ARTEMISININ; ATOVAQUONE; CALCIUM; CARRIER PROTEIN; EFLORNITHINE; ENZYME; GENE PRODUCT; ION CHANNEL; NIFURTIMOX; ORNITHINE DECARBOXYLASE; PROTEIN KINASE C; PYRIMETHAMINE; QUININE; RECEPTOR; UBIQUINOL CYTOCHROME C REDUCTASE;

AFRICAN TRYPANOSOMIASIS; APICOMPLEXA; ARTICLE; BACTERIUM IDENTIFICATION; BIOLOGICAL ACTIVITY; BIOPHYSICS; CALCIUM SIGNALING; CELL SCREENING; CHAGAS DISEASE; DRUG ACTIVITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESISTANCE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ASSAY; ERYTHROCYTE; FLUORESCENCE ANALYSIS; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GAMETOCYTE; GAMETOGENESIS; GENE SILENCING; GENE TARGETING; HIGH THROUGHPUT SCREENING; KINETOPLASTIDA; LEISHMANIASIS; MALARIA; METABOLISM; MOLECULAR DYNAMICS; NONHUMAN; PARASITE; PHENOTYPE; PROTOZOON; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; STRUCTURE ANALYSIS; TROPICAL DISEASE; TRYPANOSOMA;

CHAGAS DISEASE; DRUG DESIGN; DRUG DISCOVERY; HUMANS; LEISHMANIASIS; MALARIA; NEGLECTED DISEASES; PHENOTYPE; TRYPANOSOMIASIS, AFRICAN;

EID: 79959939890     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795429176     Document Type: Article

References (72)

1. Nwaka, S.; Hudson, A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov., 2006, 5(11), 941-955.
2. Aguero, F.; Al-Lazikani, B.; Aslett, M.; Berriman, M.; Buckner, F. S.; Campbell, R. K.; Carmona, S.; Carruthers, I. M.; Chan, A. W. E.; Chen, F.; Crowther, G. J.; Doyle, M. A.; Hertz-Fowler, C.; Hopkins, A. L.; McAllister, G.; Nwaka, S.; Overington, J. P.; Pain, A.; Paolini, G. V.; Pieper, U.; Ralph, S. A.; Riechers, A.; Roos, D. S.; Sali, A.; Shanmugam, D.; Suzuki, T.; Van Voorhis, W. C.; Verlinde, C. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat. Rev. Drug Discov., 2008, 7, 900-907.
3. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery. J. Med. Chem., 2008, 51, 3661-3680.
4. Frearson, J. A.; Brand, S.; McElroy, S. P.; Cleghorn, L. A. T.; Smid, O.; Stojanovski, L.; Price, H. P.; Guther, M. L. S.; Torrie, L. S.; Robinson, D. A.; Hallyburton, I.; Mpamhanga, C. P.; Brannigan, J. A.; Wilkinson, A. J.; Hodgkinson, M.; Hui, R.; Qiu, W.; Raimi, O. G.; Van Aalten, D. M. F.; Brenk, R.; Gilbert, I. H.; Read, K. D.; Fairlamb, A. H.; Ferguson, M. A. J.; Smith, D. F.; Wyatt, P. G. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732.
5. Schulz, M. N.; Hubbard, R. E. Recent progress in fragment-based lead discovery. Curr. Opin. Pharmacol., 2009, 9, 615-621.
6. Chakraborty, C.; Hsu, C. H.; Wen, Z. H.; Lin, C. S. Recent advances of fluorescent technologies for drug discovery and development. Curr. Pharm. Design, 2009, 15, 3552-3570.
7. Zhang, J. H.; Chung, T. D. Y.; Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen., 1999, 4, 67-73.
8. Neumann, T.; Junker, H. D.; Schmidt, K.; Sekul, R. SPR-based fragment screening: Advantages and applications. Curr. Top. Med. Chem., 2007, 7, 1630-1642.
9. Shiau, A. K.; Massari, M. E.; Ozbal, C. C. Back to basics: Labelfree technologies for small molecule screening. Comb. Chem. High Throughput Screen., 2008, 11, 231-237.
10. Wyatt, P. G.; Gilbert, I. H.; Read, K. D.; Fairlamb, A. H. Target validation: linking target and chemical properties to desired product profile. Curr. Top. Med. Chem., 2010, 11-????
11. Frearson, J. A.; Wyatt, P. G.; Gilbert, I. H.; Fairlamb, A. H. Target assessment for antiparasitic drug discovery. Trends Parasitol., 2007, 23, 589-595.
12. Burrows, J. N.; Chibale, K.; Wells, T. N. C. The state of the art in anti-malarial drug discovery and development. Current. Top. Med. Chem., 2010, 11-????
13. Berriman, M.; Ghedin, E.; Hertz-Fowler, C.; Blandin, G.; Renauld, H.; Bartholomeu, D. C.; Lennard, N. J.; Caler, E.; Hamlin, N. E.; Haas, B.; Bohme, W.; Hannick, L.; Aslett, M. A.; Shallom, J.; Marcello, L.; Hou, L. H.; Wickstead, B.; Alsmark, U. C. M.; Arrowsmith, C.; Atkin, R. J.; Barron, A. J.; Bringaud, F.; Brooks, K.; Carrington, M.; Cherevach, I.; Chillingworth, T. J.; Churcher, C.; Clark, L. N.; Corton, C. H.; Cronin, A.; Davies, R. M.; Doggett, J.; Djikeng, A.; Feldblyum, T.; Field, M. C.; Fraser, A.; Goodhead, I.; Hance, Z.; Harper, D.; Harris, B. R.; Hauser, H.; Hostetter, J.; Ivens, A.; Jagels, K.; Johnson, D.; Johnson, J.; Jones, K.; Kerhornou, A. X.; Koo, H.; Larke, N.; Landfear, S.; Larkin, C.; Leech, V.; Line, A.; Lord, A.; MacLeod, A.; Mooney, P. J.; Moule, S.; Martin, D. M. A.; Morgan, G. W.; Mungall, K.; Norbertczak, H.; Ormond, D.; Pai, G.; Peacock, C. S.; Peterson, J.; Quail, M. A.; Rabbinowitsch, E.; Rajandream, M. A.; Reitter, C.; Salzberg, S. L.; Sanders, M.; Schobel, S.; Sharp, S.; Simmonds, M.; Simpson, A. J.; Talton, L.; Turner, C. M. R.; Tait, A.; Tivey, A. R.; Van Aken, S.; Walker, D.; Wanless, D.; Wang, S. L.; White, B.; White, O.; Whitehead, S.; Woodward, J.; Wortman, J.; Adams, M. D.; Embley, T. M.; Gull, K.; Ullu, E.; Barry, J. D.; Fairlamb, A. H.; Opperdoes, F.; Barret, B. G.; Donelson, J. E.; Hall, N.; Fraser, C. M.; Melville, S. E.; El-Sayed, N. M. The genome of the African trypanosome Trypanosoma brucei. Science, 2005, 309, 416-422.
14. Ivens, A. C.; Peacock, C. S.; Worthey, E. A.; Murphy, L.; Aggarwal, G.; Berriman, M.; Sisk, E.; Rajandream, M. A.; Adlem, E.; Aert, R.; Anupama, A.; Apostolou, Z.; Attipoe, P.; Bason, N.; Bauser, C.; Beck, A.; Beverley, S. M.; Bianchettin, G.; Borzym, K.; Bothe, G.; Bruschi, C. V.; Collins, M.; Cadag, E.; Ciarloni, L.; Clayton, C.; Coulson, R. M. R.; Cronin, A.; Cruz, A. K.; Davies, R. M.; De Gaudenzi, J.; Dobson, D. E.; Duesterhoeft, A.; Fazelina, G.; Fosker, N.; Frasch, A. C.; Fraser, A.; Fuchs, M.; Gabel, C.; Goble, A.; Goffeau, A.; Harris, D.; Hertz-Fowler, C.; Hilbert, H.; Horn, D.; Huang, Y. T.; Klages, S.; Knights, A.; Kube, M.; Larke, N.; Litvin, L.; Lord, A.; Louie, T.; Marra, M.; Masuy, D.; Matthews, K.; Michaeli, S.; Mottram, J. C.; Muller-Auer, S.; Munden, H.; Nelson, S.; Norbertczak, H.; Oliver, K.; O'Neil, S.; Pentony, M.; Pohl, T. M.; Price, C.; Purnelle, B.; Quail, M. A.; Rabbinowitsch, E.; Reinhardt, R.; Rieger, M.; Rinta, J.; Robben, J.; Robertson, L.; Ruiz, J. C.; Rutter, S.; Saunders, D.; Schafer, M.; Schein, J.; Schwartz, D. C.; Seeger, K.; Seyler, A.; Sharp, S.; Shin, H.; Sivam, D.; Squares, R.; Squares, S.; Tosato, V.; Vogt, C.; Volckaert, G.; Wambutt, R.; Warren, T.; Wedler, H.; Woodward, J.; Zhou, S. G.; Zimmermann, W.; Smith, D. F.; Blackwell, J. M.; Stuart, K. D.; Barrell, B.; Myler, P. J. The genome of the kinetoplastid parasite, Leishmania major. Science, 2005, 309, 436-442.
15. El-Sayed, N. M.; Myler, P. J.; Bartholomeu, D. C.; Nilsson, D.; Aggarwal, G.; Tran, A. N.; Ghedin, E.; Worthey, E. A.; Delcher, A. L.; Blandin, G.; Westenberger, S. J.; Caler, E.; Cerqueira, G. C.; Branche, C.; Haas, B.; Anupama, A.; Arner, E.; Aslund, L.; Attipoe, P.; Bontempi, E.; Bringaud, F.; Burton, P.; Cadag, E.; Campbell, D. A.; Carrington, M.; Crabtree, J.; Darban, H.; da Silveira, J. F.; de Jong, P.; Edwards, K.; Englund, P. T.; Fazelina, G.; Feldblyum, T.; Ferella, M.; Frasch, A. C.; Gull, K.; Horn, D.; Hou, L. H.; Huang, Y. T.; Kindlund, E.; Ktingbeil, M.; Kluge, S.; Koo, H.; Lacerda, D.; Levin, M. J.; Lorenzi, H.; Louie, T.; Machado, C. R.; McCulloch, R.; McKenna, A.; Mizuno, Y.; Mottram, J. C.; Nelson, S.; Ochaya, S.; Osoegawa, K.; Pai, G.; Parsons, M.; Pentony, M.; Pettersson, U.; Pop, M.; Ramirez, J. L.; Rinta, J.; Robertson, L.; Salzberg, S. L.; Sanchez, D. O.; Seyler, A.; Sharma, R.; Shetty, J.; Simpson, A. J.; Sisk, E.; Tammi, M. T.; Tarteton, R.; Teixeira, S.; Van Aken, S.; Vogt, C.; Ward, P. N.; Wickstead, B.; Wortman, J.; White, O.; Fraser, C. M.; Stuart, K. D.; Andersson, B. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science, 2005, 309, 409-415.
16. El-Sayed, N. M.; Myler, P. J.; Blandin, G.; Berriman, M.; Crabtree, J.; Aggarwal, G.; Caler, E.; Renauld, H.; Worthey, E. A.; Hertz-Fowler, C.; Ghedin, E.; Peacock, C.; Bartholomeu, D. C.; Haas, B. J.; Tran, A. N.; Wortman, J. R.; Alsmark, U. C. M.; Angiuoli, S.; Anupama, A.; Badger, J.; Bringaud, F.; Cadag, E.; Carlton, J. M.; Cerqueira, G. C.; Creasy, T.; Delcher, A. L.; Djikeng, A.; Embley, T. M.; Hauser, C.; Ivens, A. C.; Kummerfeld, S. K.; Pereira-Leal, J. B.; Nilsson, D.; Peterson, J.; Salzberg, S. L.; Shallom, J.; Silva, J. C.; Sundaram, J.; Westenberger, S.; White, O.; Metville, S. E.; Donelson, J. E.; Andersson, B.; Stuart, K. D.; Hall, N. Comparative genomics of trypanosomatid parasitic protozoa. Science, 2005, 309, 404-409.
17. Pepin, J.; Guern, C.; Milord, F.; Schechter, P. J. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness. Lancet, 1987, 2, 1431-1433.
18. Dardonville, C. Recent advances in antitrypanosomal chemotherapy: patent literature 2002-2004. Expert Opin. Ther. Pat., 2005, 15(9), 1241-1257.
19. Renslo, A. R.; McKerrow, J. H. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol., 2006, 2, 701-710.
20. Richardson, J. L.; Nett, I. R. E.; Jones, D. C.; Abdille, M. H.; Gilbert, I. H.; Fairlamb, A. H. Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis. Chem Med Chem 2009, 4, 1333-1340.
21. Patterson, S.; Jones, D. C.; Shanks, E. J.; Frearson, J. A.; Gilbert, I. H.; Wyatt, P. G.; Fairlamb, A. H. Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductase. ChemMedChem, 2009, 4, 1341-1353.
22. Spinks, D.; Shanks, E. J.; Cleghorn, L. A. T.; McElroy, S.; Jones, D.; James, D.; Fairlamb, A. H.; Frearson, J. A.; Wyatt, P. G.; Gilbert, I. H. Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma brucei. ChemMedChem, 2009, 4, 2060-2069.
23. Holloway, G. A.; Baell, J. B.; Fairlamb, A. H.; Novello, P. M.; Parisot, J. P.; Richardson, J.; Watson, K. G.; Street, I. P. Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorg. Med. Chem. Lett., 2007, 17, 1422-1427.
24. Holloway, G. A.; Charman, W. N.; Fairlamb, A. H.; Brun, R.; Kaiser, M.; Kostewicz, E.; Novello, P. M.; Parisot, J. P.; Richardson, J.; Street, I. P.; Watson, K. G.; Baell, J. B. Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity. Antimicrob. Agents Chemother,. 2009, 53, 2824-2833.
25. Mpamhanga, C. P.; Spinks, D.; Tulloch, L. B.; Shanks, E. J.; Robinson, D. A.; Collie, I. T.; Fairlamb, A. H.; Wyatt, P. G.; Frearson, J. A.; Hunter, W. N.; Gilbert, I. H.; Brenk, R. One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening. J. Med. Chem., 2009, 52, 4454-4465.
26. Tulloch, L. B.; Martini, V. P.; Iulek, J.; Huggan, J. K.; Lee, J. H.; Gibson, C. L.; Smith, T. K.; Suckling, C. J.; Hunter, W. N. Structure-based design of pteridine reductase inhibitors targeting african sleeping sickness and the leishmaniases. J. Med. Chem., 2009, 53, 221-229.
27. Hardy, L. W.; Matthews, W.; Nare, B.; Beverley, S. M. Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways. Exp. Parasitol., 1997, 87, 157-169.
28. Cavazzuti, A.; Paglietti, G.; Hunter, W. N.; Gamarro, F.; Piras, S.; Loriga, M.; Alleca, S.; Corona, P.; McLuskey, K.; Tulloch, L.; Gibellini, F.; Ferrari, S.; Costin, M. P. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc. Natl. Acad. Sci. USA, 2008, 105, 1448-1453.
29. Sirawaraporn, W.; Sertsrivanich, R.; Booth, R. G.; Hansch, C.; Neal, R. A.; Santi, D. V. Selective inhibtion of Leishmania dihydrofolate reductase and Leishmania growth by 5-benzyl-2,4-diaminopyrimidines. Mol. Biochem. Parasitol., 1988, 31, 79.
30. Chowdhury, S. F.; Guerrero, R. H.; Brun, R.; Ruiz-Perez, L. M.; Pacanowska, D. G.; Gilbert, I. H. Synthesis and testing of 5-benzyl-2,4-diaminopyrimidines as potential inhibitors of leishmanial and trypanosomal dihydrofolate reductase. J. Enzym. Inhib. Med. Chem., 2002, 17, 293-302.
31. Chowdhury, S. F.; Villamor, V. B.; Guerrero, R. H.; Leal, I.; Brun, R.; Croft, S. L.; Goodman, J. M.; Maes, L.; Ruiz-Perez, L. M.; Pacanowska, D. G.; Gilbert, I. H. Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase. J. Med. Chem., 1999, 42, 4300-4312.
32. Khabnadideh, S.; Pez, D.; Musso, A.; Brun, R.; Perez, L. M. R.; Gonzalez-Pacanowska, D.; Gilbert, I. H. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase. Bioorg. Med. Chem., 2005, 13, 2637-2649.
33. Senkovich, O.; Bhatia, V.; Garg, N.; Chattopadhyay, D. Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: Prospect for chemotherapy of Chagas' disease. Antimicrob. Agents Chemother., 2005, 49, 3234-3238.
34. Yuthavong, Y.; Kamchonwongpaisan, S.; Leartsakulpanich, U.; Chitnumsub, P. Folate metabolism as a source of molecular targets for antimalarials. Future Microbiol., 2006, 1, 113-125.
35. Torrie, L. S.; Wyllie, S.; Spinks, D.; Oza, S. L.; Thompson, S.; Harrison, J. R.; Gilbert, I. H.; Wyatt, P. G.; Fairlamb, A. H.; Frearson, J. A. Chemical validation of trypanothione synthetase. J. Biol. Chem., 2009, 284, 36137-36145.
36. Urbina, J. A. Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz, m 2009, 104, 311-318.
37. Hucke, O.; Gelb, M. H.; Verlinde, C.; Buckner, F. S. The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas disease. J. Med. Chem., 2005, 48, 5415-5418.
38. Kraus, J. M.; Verlinde, C.; Karimi, M.; Lepesheva, G. I.; Gelb, M. H.; Buckner, F. S. Rational modification of a candidate cancer drug for use against chagas disease. J. Med. Chem., 2009, 52, 1639-1647.
39. Mott, B. T.; Ferreira, R. S.; Simeonov, A.; Jadhav, A.; Ang, K. K.-H.; Leister, W.; Shen, M.; Silveira, J. T.; Doyle, P. S.; Arkin, M. R.; McKerrow, J. H.; Inglese, J.; Austin, C. P.; Thomas, C. J.; Shoichet, B. K.; Maloney, D. J. Identification and optimization of inhibitors of trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB. J. Med. Chem. 2009, 53, 52-60.
40. Nowicki, M. W.; Tulloch, L. B.; Worralll, L.; McNae, I. W.; Hannaert, V.; Michels, P. A. M.; Fothergill-Gilmore, L. A.; Walkinshaw, M. D.; Turner, N. J. Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis. 2008, Bioorg. Med. Chem., 16, 5050-5061.
41. Freitas, R. F.; Prokopczyk, I. M.; Zottis, A.; Oliva, G.; Andricopulo, A. D.; Trevisan, M. T. S.; Vilegas, W.; Silva, M. G. V.; Montanari, C. A. Discovery of novel Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase inhibitors. Bioorg. Med. Chem., 2009, 17, 2476-2482.
42. Bressi, J. C.; Choe, J.; Hough, M. T.; Buckner, F. S.; Van Voorhis, W. C.; Verlinde, C.; Hol, W. G. J.; Gelb, M. H. Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: Elucidation of a novel binding mode for a 2-amino-N-6-substituted adenosine. J. Med. Chem., 2000, 43, 4135-4150.
43. Aronov, A. M.; Suresh, S.; Buckner, F. S.; Van Voorhis, W. C.; Verlinde, C.; Opperdoes, F. R.; Hol, W. G. J.; Gelb, M. H. Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase. Proc. Natl. Acad. Sci. USA, 1999, 96, 4273-4278.
44. Barker, R. H.; Liu, H. L.; Hirth, B.; Celatka, C. A.; Fitzpatrick, R.; Xiang, Y. B.; Willert, E. K.; Phillips, M. A.; Kaiser, M.; Bacchi, C. J.; Rodriguez, A.; Yarlett, N.; Klinger, J. D.; Sybertz, E. Novel SAdenosylmethionine Decarboxylase Inhibitors for the Treatment of Human African Trypanosomiasis. Antimicrob. Agents Chemother., 2009, 53, 2052-2058.
45. Hirth, B.; Barker, R. H.; Celatka, C. A.; Klinger, J. D.; Liu, H. L.; Nare, B.; Nijjar, A.; Phillips, M. A.; Sybertz, E.; Willert, E. K.; Xiang, Y. B. Discovery of new S-adenosylmethionine decarboxylase inhibitors for the treatment of Human African Trypanosomiasis (HAT). Bioorg. Med. Chem. Lett., 2009, 19, 2916-2919.
46. Bitonti, A. J.; Byers, T. L.; Bush, T. L.; Casara, P. J.; Bacchi, C. J.; Clarkson, A. B.; McCann, P. P.; Sjoerdsma, A. Cure of Trypanosoma-Brucei-Brucei and Trypanosoma-Brucei-Rhodesiense Infections in Mice with an Irreversible Inhibitor of SAdenosylmethionine Decarboxylase. Antimicrob. Agents Chemother., 1990, 34, 1485-1490.
47. Grant, K. M.; Dunion, M. H.; Yardley, V.; Skaltsounis, A. L.; Marko, D.; Eisenbrand, G.; Croft, S. L.; Meijer, L.; Mottram, J. C. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: Chemical library screen and antileishmanial activity. Antimicrob. Agents Chemother., 2004, 48, 3033-3042.
48. Baldwin, J.; Michnoff, C. H.; Malmquist, N. A.; White, J.; Roth, M. G.; Rathod, P. K.; Phillips, M. A. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem., 2005, 280, 21847-21853.
49. Gujjar, R.; Marwaha, A.; El Mazouni, F.; White, J.; White, K. L.; Creason, S.; Shackleford, D. M.; Baldwin, J.; Charman, W. N.; Buckner, F. S.; Charman, S.; Rathod, P. K.; Phillips, M. A. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J. Med. Chem., 2009, 52, 1864-1872.
50. Yeates, C. L.; Batchelor, J. F.; Capon, E. C.; Cheesman, N. J.; Fry, M.; Hudson, A. T.; Pudney, M.; Trimming, H.; Woolven, J.; Bueno, J. M.; Chicharro, J.; Fernandez, E.; Fiandor, J. M.; Gargallo-Viola, D.; de las Heras, F. G.; Herreros, E.; Leon, M. L. Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. J. Med. Chem., 2008, 51, 2845-2852.
51. Kerr, I. D.; Lee, J. H.; Pandey, K. C.; Harrison, A.; Sajid, M.; Rosenthal, P. J.; Brinen, L. S. Structures of falcipain-2 and falcipain-3 bound to small molecule Inhibitors: implications for substrate specificity. J. Med. Chem., 2009, 52, 852-857.
52. Patel, V.; Mazitschek, R.; Coleman, B.; Nguyen, C.; Urgaonkar, S.; Cortese, J.; Barker, R. H.; Greenberg, E.; Tang, W. P.; Bradner, J. E.; Schreiber, S. L.; Duraisingh, M. T.; Wirth, D. F.; Clardy, J. Identification and characterization of small molecule inhibitors of a class I histone deacetylase from plasmodium falciparum. J. Med. Chem., 2009, 52, 2185-2187.
53. Yeoh, S.; O'Donnell, R. A.; Koussis, K.; Dluzewski, A. R.; Ansell, K. H.; Osborne, S. A.; Hackett, F.; Withers-Martinez, C.; Mitchell, G. H.; Bannister, L. H.; Bryans, J. S.; Kettleborough, C. A.; Blackman, M. J. Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes. Cell, 2007, 131, 1072-1083.
54. Schrattenholz, A.; Soskic, V. What does systems biology mean for drug development? Curr. Med. Chem., 2008, 15, 1520-1528.
55. Kaelin, W. G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev., Cancer, 2005, 5, 689-698.
56. Checchi, F.; Piola, P.; Ayikoru, H.; Thomas, F.; Legros, D.; Priotto, G. Nifurtimox plus eflornithine for late-stage sleeping sickness in uganda: A case series. PLoS Negl. Trop. Dis., 2007, 1(2) e64.
57. Barros, T. P.; Alderton, W. K.; Reynolds, H. M.; Roach, A. G.; Berghmans, S. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br. J. Pharmacol., 2008, 154, 1400-1413.
58. Akerman, M. E.; Chan, W. C. W.; Laakkonen, P.; Bhatia, S. N.; Ruoslahti, E. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA, 2002, 99, 12617-12621.
59. Gwinn, M. R.; Vallyathan, V. Nanoparticles: Health effects-Pros and cons. Environ. Health Perspect., 2006, 114, 1818-1825.
60. Starkuviene, V.; Pepperkok, R. The potential of high-content highthroughput microscopy in drug discovery. Br. J. Pharmacol., 2007, 152, 62-71.
61. Barbe, L.; Lundberg, E.; Oksvold, P.; Stenius, A.; Lewin, E.; Bjorling, E.; Asplund, A.; Ponten, F.; Brismar, H.; Uhlen, M.; Andersson-Svahn, H. Toward a confocal subcellular atlas of the human proteome. Mol. Cell. Proteomics, 2008, 7, 499-508.
62. Sekar, R. B.; Periasamy, A. Fluorescence resonance energy transfer (FRET) microscopy imaging of live cell protein localizations. J. Cell. Biol., 2003, 160, 629-633.
63. Ciambrone, G. J.; Liu, V. F.; Lin, D. C.; McGuinness, R. P.; Leung, G. K.; Pitchford, S. Cellular dielectric spectroscopy: A powerful new approach to label-free cellular analysis. J. Biomol. Screen., 2004, 9, 467-480.
64. Tarun, A. S.; Peng, X.; Dumpit, R. F.; Ogata, Y.; Silva-Rivera, H.; Camargo, N.; Daly, T. M.; Bergman, L. W.; Kappe, S. H. I. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc. Natl. Acad. Sci. USA, 2008, 105, 305-310.
65. Billker, O.; Dechamps, S.; Tewari, R.; Wenig, G.; Franke-Fayard, B.; Brinkmann, V. Calcium and a calcium-dependent protein kinase regulate gamete formation and mosquito transmission in a malaria parasite. Cell, 2004, 117, 503-514.
66. Wells, T. N. C.; Burrows, J. N.; Baird, J. K. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol., 2010, 26, 145-151.
67. Plouffe, D.; Brinker, A.; McNamara, C.; Henson, K.; Kato, N.; Kuhen, K.; Nagle, A.; Adrian, F.; Matzen, J. T.; Anderson, P.; Nam, T. G.; Gray, N. S.; Chatterjee, A.; Janes, J.; Yan, S. F.; Trager, R.; Caldwell, J. S.; Schultz, P. G.; Zhou, Y.; Winzeler, E. A. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl. Acad. Sci. USA, 2008, 105, 9059-9064.
68. Baniecki, M. L.; Wirth, D. F.; Clardy, J. High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob. Agents Chemother., 2007, 51, 716-723.
69. Gamo, F. J.; Sanz, L. M.; Vidal, J.; de Cozar, C.; Alvarez, E.; Lavandera, J. L.; Vanderwall, D. E.; Green, D. V. S.; Kumar, V.; Hasan, S.; Brown, J. R.; Peishoff, C. E.; Cardon, L. R.; Garcia-Bustos, J. F. Thousands of chemical starting points for antimalarial lead identification. Nature, 2010, 465, 305-U56.
70. Bettiol, E.; Samanovic, M.; Murkin, A. S.; Raper, J.; Buckner, F.; Rodriguez, A. Identification of three classes of heteroaromatic compounds with activity against intracellular trypanosoma cruzi by chemical library screening. PLoS Negl. Trop, Dis., 2009, 3(2), e384.
71. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol., 2007, 25, 1035-1044.
72. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov., 2007, 6, 29-40.